Communicating the impact of
Multicancer Early Detection technologies
on improving cancer detection
and outcomes for all
Multicancer Early Detection (MCED) is an emerging set of technologies that — with a blood draw, breath, urine, saliva, or stool sample — can enable clinicians to rapidly screen for multiple cancer types at once. But to ensure maximum uptake and smooth rollout of these tools, we must collaborate with a wide group of stakeholders from across the healthcare continuum.
OUR MISSION
To reduce the burden of cancer by evaluating how MCED technologies
may improve cancer detection, treatment, and care to benefit all people.
OUR OBJECTIVES
To evaluate and assess the benefits and risks, potential outcomes, costs, and value associated with introducing novel MCED technologies into society and clinical care;
To develop guidance for the potential introduction of these technologies into clinical care, including understanding public perceptions of MCED technologies and these technologies’ potential to improve or exacerbate health disparities;
To accelerate additional lessons and evaluations on how MCED technologies could potentially improve outcomes for all people.
Meet Our Leadership
The Executive Committee is responsible for general oversight of the consortium. The committee is comprised of a cross-section of healthcare and research professionals dedicated to MCED technology awareness and education.
Our Work
-
Clinical Utility Workgroup
Thier objective is to engage and leverage the healthcare community knowledge to design interim clinical utility frameworks for using MCED technologies.
-
Care Delivery Workgroup
Their objective is to develop guidance and associated clinical workflows for the technologies’ introduction into clinical care as both a screen and diagnostic test.
-
Health Equity Workgroup
Their objective is to evaluate and develop guidance on reducing healthcare disparities with the use of MCED technology.
-
Communications Workgroup
Their objective is to promote our work and educate both the public and the clinical community.